(1) Moyè LA. End-point interpretation in clinical trials: the case for discipline. Control Clin trials 1999 20:40-9 (2) Freemantle N..Interpreting the results of secondaru end points and sobgroup analyses in clinical trials: should we lock the crazy aunt in the attic?.BMJ 322 2001 322:989-91 (3) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Maior Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic - JAMA, 2002 - 288:2981 (4) Furberg CD , Byington RP What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. Circulation. 1983 Jun;67(6 Pt 2):98-101. (5) Sackett DL. Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only forlula a clinician-trialist is ever lickely to need (or understand). JAMC 2001 165(9):1226-37 (6) Fischer LD. Carvedilol and the Food and drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. Contr Clin Trials 1999 20:16-39 (7) University of Washington. RCDRC Guidelines for Clinic Trial Designs http://depts.washington.edu/rcdrc/app.html (8) Björn Dahlöf et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendromethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial'. Lancet 2005; 366: 895–906
Home
Entra
Iscriviti
Versione stampabile
